unknown
Stage
1
Investors
About
Vaximm develops next-generation oral cancer immunotherapies based on its proprietary Immune-Enhancer™ technology to activate immune responses against tumors.
Explore Vaximm's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.